| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 240 | 2024 | 20982 | 9.110 |
Why?
|
| Receptor, erbB-2 | 72 | 2024 | 2553 | 5.840 |
Why?
|
| Aromatase Inhibitors | 30 | 2024 | 513 | 4.350 |
Why?
|
| Antineoplastic Agents, Hormonal | 34 | 2022 | 1520 | 4.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 84 | 2024 | 11733 | 3.860 |
Why?
|
| Chemotherapy, Adjuvant | 74 | 2024 | 3512 | 3.510 |
Why?
|
| Receptors, Estrogen | 31 | 2024 | 2208 | 3.260 |
Why?
|
| Tamoxifen | 29 | 2022 | 965 | 3.230 |
Why?
|
| Medical Oncology | 33 | 2024 | 2320 | 3.220 |
Why?
|
| Antineoplastic Agents | 62 | 2021 | 13632 | 2.400 |
Why?
|
| Receptors, Progesterone | 20 | 2024 | 1129 | 2.280 |
Why?
|
| Paclitaxel | 29 | 2024 | 1730 | 1.970 |
Why?
|
| Neoadjuvant Therapy | 24 | 2024 | 2827 | 1.670 |
Why?
|
| Quinazolines | 12 | 2014 | 1371 | 1.420 |
Why?
|
| Genes, erbB-2 | 7 | 2014 | 162 | 1.240 |
Why?
|
| Neoplasms | 32 | 2022 | 22142 | 1.200 |
Why?
|
| Antibodies, Monoclonal | 30 | 2011 | 9187 | 1.160 |
Why?
|
| Neoplasm Staging | 50 | 2024 | 11119 | 1.130 |
Why?
|
| Ovary | 6 | 2016 | 957 | 1.090 |
Why?
|
| Practice Guidelines as Topic | 19 | 2021 | 7400 | 1.070 |
Why?
|
| Disease-Free Survival | 39 | 2024 | 6819 | 1.030 |
Why?
|
| Female | 239 | 2024 | 392552 | 1.020 |
Why?
|
| Estrogen Receptor alpha | 2 | 2023 | 582 | 0.970 |
Why?
|
| Vinblastine | 11 | 2013 | 488 | 0.930 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2023 | 9278 | 0.910 |
Why?
|
| Humans | 296 | 2024 | 761222 | 0.900 |
Why?
|
| Postmenopause | 14 | 2022 | 2514 | 0.840 |
Why?
|
| Carcinoma | 7 | 2011 | 2330 | 0.840 |
Why?
|
| Cyclophosphamide | 17 | 2023 | 2219 | 0.830 |
Why?
|
| Taxoids | 7 | 2011 | 668 | 0.820 |
Why?
|
| Anthracyclines | 5 | 2013 | 285 | 0.790 |
Why?
|
| Androstadienes | 6 | 2018 | 348 | 0.740 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2019 | 168 | 0.740 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2020 | 131 | 0.730 |
Why?
|
| Mastectomy | 22 | 2024 | 1818 | 0.730 |
Why?
|
| Mastectomy, Segmental | 11 | 2019 | 955 | 0.690 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2024 | 559 | 0.680 |
Why?
|
| Clinical Trials as Topic | 20 | 2022 | 8002 | 0.670 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2024 | 348 | 0.640 |
Why?
|
| Nitriles | 6 | 2021 | 971 | 0.620 |
Why?
|
| Drug Approval | 6 | 2018 | 812 | 0.620 |
Why?
|
| Triazoles | 6 | 2021 | 902 | 0.610 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2012 | 2047 | 0.610 |
Why?
|
| Neoplasm Metastasis | 23 | 2020 | 4909 | 0.600 |
Why?
|
| Piperazines | 4 | 2024 | 2522 | 0.600 |
Why?
|
| Pyrroles | 4 | 2024 | 1124 | 0.600 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2013 | 107 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2024 | 5301 | 0.570 |
Why?
|
| Indoles | 4 | 2010 | 1830 | 0.550 |
Why?
|
| Pyridines | 4 | 2024 | 2872 | 0.550 |
Why?
|
| Premenopause | 12 | 2022 | 1039 | 0.530 |
Why?
|
| Neutropenia | 4 | 2023 | 885 | 0.530 |
Why?
|
| Carcinoma, Ductal, Breast | 7 | 2020 | 1084 | 0.530 |
Why?
|
| Receptors, Steroid | 2 | 2014 | 155 | 0.520 |
Why?
|
| Expert Testimony | 4 | 2019 | 365 | 0.520 |
Why?
|
| Patient Selection | 5 | 2019 | 4246 | 0.510 |
Why?
|
| Cancer Care Facilities | 3 | 2013 | 422 | 0.500 |
Why?
|
| Doxorubicin | 15 | 2020 | 2224 | 0.490 |
Why?
|
| Arthralgia | 3 | 2008 | 461 | 0.480 |
Why?
|
| Combined Modality Therapy | 20 | 2024 | 8519 | 0.480 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2009 | 410 | 0.470 |
Why?
|
| Biomedical Research | 4 | 2017 | 3434 | 0.460 |
Why?
|
| Lymphatic Metastasis | 9 | 2022 | 2913 | 0.450 |
Why?
|
| Deoxycytidine | 7 | 2009 | 878 | 0.450 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2006 | 629 | 0.450 |
Why?
|
| Estradiol | 4 | 2019 | 1937 | 0.440 |
Why?
|
| Prognosis | 29 | 2024 | 29688 | 0.440 |
Why?
|
| Endocrine System | 1 | 2014 | 113 | 0.430 |
Why?
|
| Thoracic Wall | 1 | 2015 | 202 | 0.430 |
Why?
|
| Cost Control | 1 | 2015 | 627 | 0.410 |
Why?
|
| Mass Media | 3 | 2011 | 303 | 0.410 |
Why?
|
| Treatment Outcome | 45 | 2024 | 64681 | 0.410 |
Why?
|
| Continuity of Patient Care | 3 | 2011 | 1069 | 0.400 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2022 | 926 | 0.400 |
Why?
|
| Drug Administration Schedule | 14 | 2017 | 4851 | 0.390 |
Why?
|
| Middle Aged | 85 | 2024 | 220858 | 0.390 |
Why?
|
| Survivors | 5 | 2013 | 2369 | 0.380 |
Why?
|
| Aged | 65 | 2024 | 169292 | 0.380 |
Why?
|
| Ketones | 2 | 2020 | 182 | 0.380 |
Why?
|
| Communication | 3 | 2011 | 3872 | 0.380 |
Why?
|
| Furans | 2 | 2020 | 201 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2018 | 10218 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 8531 | 0.380 |
Why?
|
| Off-Label Use | 1 | 2013 | 185 | 0.370 |
Why?
|
| Sentinel Lymph Node Biopsy | 9 | 2022 | 732 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 8 | 2024 | 2813 | 0.370 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 5665 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2012 | 3493 | 0.350 |
Why?
|
| Survival Analysis | 15 | 2019 | 10088 | 0.350 |
Why?
|
| Adult | 69 | 2024 | 221120 | 0.340 |
Why?
|
| Neoplasm Invasiveness | 10 | 2020 | 3590 | 0.330 |
Why?
|
| Drug Therapy | 1 | 2012 | 503 | 0.330 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 2004 | 0.330 |
Why?
|
| Drug Costs | 2 | 2015 | 1183 | 0.330 |
Why?
|
| Disclosure | 2 | 2012 | 747 | 0.330 |
Why?
|
| Filgrastim | 4 | 2020 | 132 | 0.320 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 212 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2019 | 646 | 0.320 |
Why?
|
| Pharmacy | 1 | 2010 | 91 | 0.320 |
Why?
|
| Critical Pathways | 1 | 2012 | 475 | 0.310 |
Why?
|
| Anemia | 3 | 2007 | 1504 | 0.310 |
Why?
|
| Specialty Boards | 1 | 2010 | 235 | 0.310 |
Why?
|
| Avian Sarcoma Viruses | 6 | 1995 | 76 | 0.310 |
Why?
|
| Lymph Node Excision | 8 | 2022 | 1270 | 0.310 |
Why?
|
| Lymph Nodes | 6 | 2022 | 3461 | 0.310 |
Why?
|
| Allied Health Personnel | 1 | 2009 | 154 | 0.300 |
Why?
|
| Patients | 2 | 2012 | 906 | 0.290 |
Why?
|
| Carcinoma, Lobular | 3 | 2023 | 480 | 0.290 |
Why?
|
| Leuprolide | 1 | 2009 | 312 | 0.290 |
Why?
|
| Risk Assessment | 13 | 2019 | 24022 | 0.290 |
Why?
|
| Quality of Life | 16 | 2024 | 13367 | 0.290 |
Why?
|
| Piperidines | 3 | 2012 | 1656 | 0.290 |
Why?
|
| Hormones | 4 | 2022 | 868 | 0.280 |
Why?
|
| Methotrexate | 6 | 2023 | 1718 | 0.280 |
Why?
|
| Radiotherapy | 6 | 2019 | 1500 | 0.280 |
Why?
|
| Certification | 1 | 2010 | 418 | 0.280 |
Why?
|
| Maytansine | 2 | 2021 | 86 | 0.270 |
Why?
|
| Survival Rate | 13 | 2019 | 12728 | 0.270 |
Why?
|
| Complementary Therapies | 3 | 2009 | 487 | 0.270 |
Why?
|
| Musculoskeletal System | 1 | 2008 | 188 | 0.270 |
Why?
|
| Mammography | 5 | 2009 | 2430 | 0.270 |
Why?
|
| Hormone Replacement Therapy | 2 | 2010 | 751 | 0.260 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2005 | 349 | 0.260 |
Why?
|
| Lymphopenia | 1 | 2008 | 282 | 0.260 |
Why?
|
| Ethics, Medical | 1 | 2011 | 785 | 0.260 |
Why?
|
| Hospice Care | 1 | 2013 | 678 | 0.260 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2024 | 1784 | 0.260 |
Why?
|
| Advance Care Planning | 1 | 2013 | 697 | 0.250 |
Why?
|
| Benchmarking | 1 | 2012 | 1045 | 0.250 |
Why?
|
| Drug Industry | 1 | 2012 | 788 | 0.250 |
Why?
|
| Enzyme Inhibitors | 6 | 2011 | 3702 | 0.250 |
Why?
|
| Patient Care Management | 1 | 2008 | 303 | 0.240 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 1008 | 0.240 |
Why?
|
| Carbazoles | 1 | 2006 | 220 | 0.240 |
Why?
|
| Physicians | 2 | 2013 | 4584 | 0.230 |
Why?
|
| Checklist | 1 | 2011 | 828 | 0.230 |
Why?
|
| Quinolines | 1 | 2010 | 764 | 0.230 |
Why?
|
| Fluorouracil | 7 | 2019 | 1642 | 0.230 |
Why?
|
| Molecular Biology | 1 | 2008 | 573 | 0.230 |
Why?
|
| Hematinics | 1 | 2007 | 282 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 2636 | 0.230 |
Why?
|
| Conflict of Interest | 1 | 2008 | 554 | 0.220 |
Why?
|
| Educational Measurement | 1 | 2010 | 1250 | 0.220 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 1187 | 0.220 |
Why?
|
| Chromans | 1 | 2003 | 117 | 0.210 |
Why?
|
| Erythropoiesis | 1 | 2007 | 683 | 0.210 |
Why?
|
| Markov Chains | 5 | 2020 | 965 | 0.210 |
Why?
|
| Gene Products, gag | 3 | 1992 | 312 | 0.210 |
Why?
|
| Oncology Service, Hospital | 2 | 2013 | 57 | 0.210 |
Why?
|
| Decision Making | 3 | 2020 | 3931 | 0.210 |
Why?
|
| Follow-Up Studies | 20 | 2023 | 39127 | 0.210 |
Why?
|
| Pediatrics | 1 | 2018 | 3590 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 677 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 6486 | 0.200 |
Why?
|
| Carboplatin | 2 | 2022 | 793 | 0.200 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 2756 | 0.200 |
Why?
|
| Physician-Patient Relations | 3 | 2013 | 3253 | 0.200 |
Why?
|
| Blood Platelets | 1 | 2012 | 2477 | 0.190 |
Why?
|
| Health Care Costs | 2 | 2012 | 3239 | 0.190 |
Why?
|
| Societies, Medical | 7 | 2017 | 3923 | 0.190 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 58952 | 0.190 |
Why?
|
| Maintenance | 1 | 2021 | 25 | 0.190 |
Why?
|
| Erythropoietin | 1 | 2005 | 719 | 0.180 |
Why?
|
| Health Policy | 2 | 2012 | 2679 | 0.180 |
Why?
|
| Amenorrhea | 3 | 2021 | 483 | 0.180 |
Why?
|
| Carcinoma in Situ | 2 | 2020 | 791 | 0.180 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 1463 | 0.180 |
Why?
|
| Palliative Care | 2 | 2013 | 3599 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2011 | 2688 | 0.180 |
Why?
|
| Disease Progression | 10 | 2024 | 13511 | 0.180 |
Why?
|
| United States | 24 | 2018 | 72341 | 0.170 |
Why?
|
| Mass Screening | 2 | 2021 | 5426 | 0.170 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 460 | 0.170 |
Why?
|
| Medication Errors | 1 | 2006 | 783 | 0.170 |
Why?
|
| Interleukin-4 | 3 | 1993 | 1154 | 0.170 |
Why?
|
| Radiodermatitis | 1 | 2000 | 60 | 0.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2002 | 258 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2021 | 943 | 0.160 |
Why?
|
| Administration, Oral | 6 | 2015 | 4015 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2009 | 2220 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2426 | 0.160 |
Why?
|
| United States Food and Drug Administration | 5 | 2018 | 1662 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2013 | 915 | 0.150 |
Why?
|
| Endopeptidases | 5 | 1994 | 766 | 0.150 |
Why?
|
| Disease Management | 5 | 2020 | 2507 | 0.150 |
Why?
|
| Feasibility Studies | 3 | 2019 | 5250 | 0.150 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 1997 | 13 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 2527 | 0.140 |
Why?
|
| Axilla | 5 | 2022 | 624 | 0.140 |
Why?
|
| Annual Reports as Topic | 1 | 2017 | 36 | 0.140 |
Why?
|
| Patient Preference | 2 | 2016 | 927 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 592 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14675 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2014 | 1567 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 360 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 4 | 2023 | 988 | 0.130 |
Why?
|
| Time Factors | 10 | 2022 | 39957 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 620 | 0.130 |
Why?
|
| Prospective Studies | 14 | 2023 | 54437 | 0.130 |
Why?
|
| Thiazoles | 1 | 2003 | 1517 | 0.130 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 12474 | 0.130 |
Why?
|
| Fatigue | 4 | 2018 | 1550 | 0.130 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 1993 | 976 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 801 | 0.120 |
Why?
|
| Research Support as Topic | 2 | 2017 | 697 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 364 | 0.120 |
Why?
|
| Patient Advocacy | 2 | 2020 | 358 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 2317 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 5426 | 0.120 |
Why?
|
| Genetic Testing | 5 | 2019 | 3537 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2010 | 4788 | 0.120 |
Why?
|
| Early Detection of Cancer | 4 | 2017 | 3198 | 0.120 |
Why?
|
| Perimenopause | 1 | 2016 | 142 | 0.120 |
Why?
|
| Cannabinoids | 1 | 2017 | 172 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 610 | 0.110 |
Why?
|
| Amniotic Fluid | 2 | 1986 | 378 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2007 | 3976 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2011 | 2643 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2022 | 8642 | 0.110 |
Why?
|
| Patient Care Team | 5 | 2013 | 2515 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2009 | 4487 | 0.110 |
Why?
|
| Immune Tolerance | 2 | 1993 | 2307 | 0.110 |
Why?
|
| HIV Protease | 4 | 1995 | 97 | 0.110 |
Why?
|
| Antibody Formation | 3 | 1993 | 1391 | 0.110 |
Why?
|
| Switzerland | 1 | 2013 | 319 | 0.100 |
Why?
|
| Age Factors | 6 | 2019 | 18384 | 0.100 |
Why?
|
| Consensus | 2 | 2023 | 3134 | 0.100 |
Why?
|
| Phospholipids | 2 | 1986 | 784 | 0.100 |
Why?
|
| Gene Products, pol | 1 | 1992 | 43 | 0.100 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 129 | 0.100 |
Why?
|
| Anonymous Testing | 1 | 2011 | 10 | 0.100 |
Why?
|
| Preoperative Period | 1 | 2014 | 551 | 0.100 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2011 | 107 | 0.100 |
Why?
|
| Genes, gag | 1 | 1991 | 55 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 10756 | 0.100 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2011 | 36 | 0.100 |
Why?
|
| Genotype | 4 | 2019 | 12985 | 0.100 |
Why?
|
| Risk Factors | 15 | 2022 | 74241 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 161 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2024 | 3027 | 0.100 |
Why?
|
| Interdisciplinary Communication | 4 | 2013 | 931 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 563 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2010 | 296 | 0.100 |
Why?
|
| Environment Design | 1 | 2013 | 173 | 0.090 |
Why?
|
| Hematologic Diseases | 2 | 2008 | 496 | 0.090 |
Why?
|
| Dyspnea | 1 | 2019 | 1347 | 0.090 |
Why?
|
| Advisory Committees | 3 | 2010 | 788 | 0.090 |
Why?
|
| Dissent and Disputes | 1 | 2011 | 148 | 0.090 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 788 | 0.090 |
Why?
|
| Inservice Training | 1 | 2013 | 375 | 0.090 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1991 | 238 | 0.090 |
Why?
|
| Body Weight | 1 | 2021 | 4618 | 0.090 |
Why?
|
| Self Report | 3 | 2018 | 3727 | 0.090 |
Why?
|
| New York | 1 | 2012 | 875 | 0.090 |
Why?
|
| Nausea | 2 | 2017 | 678 | 0.090 |
Why?
|
| Congresses as Topic | 2 | 2012 | 803 | 0.080 |
Why?
|
| Quality of Health Care | 3 | 2012 | 4321 | 0.080 |
Why?
|
| Retrospective Studies | 12 | 2023 | 80675 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2006 | 858 | 0.080 |
Why?
|
| Cognition | 1 | 2007 | 6988 | 0.080 |
Why?
|
| Electronic Mail | 1 | 2011 | 213 | 0.080 |
Why?
|
| Fertility | 2 | 2016 | 768 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 2802 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2019 | 709 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 6504 | 0.080 |
Why?
|
| Lymphocyte Activation | 4 | 1993 | 5478 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 9417 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2011 | 536 | 0.080 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 6341 | 0.080 |
Why?
|
| California | 1 | 2012 | 1431 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2015 | 2217 | 0.080 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 150 | 0.080 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2008 | 58 | 0.080 |
Why?
|
| Heart Diseases | 3 | 2010 | 2795 | 0.080 |
Why?
|
| Endpoint Determination | 2 | 2012 | 590 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2015 | 628 | 0.070 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 111 | 0.070 |
Why?
|
| Young Adult | 9 | 2021 | 59222 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 1111 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 3 | 1992 | 1967 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 442 | 0.070 |
Why?
|
| Sarcoma | 1 | 2019 | 1800 | 0.070 |
Why?
|
| Ultrasonography, Mammary | 1 | 2009 | 239 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2020 | 3727 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2011 | 454 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2023 | 12952 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2008 | 367 | 0.070 |
Why?
|
| Vasodilation | 1 | 2011 | 966 | 0.070 |
Why?
|
| Mutation | 6 | 2023 | 30004 | 0.070 |
Why?
|
| Waiting Lists | 1 | 2011 | 766 | 0.070 |
Why?
|
| Antigens | 1 | 1992 | 1441 | 0.070 |
Why?
|
| Policy | 1 | 2010 | 506 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2019 | 3813 | 0.070 |
Why?
|
| Home Care Services | 1 | 2013 | 647 | 0.070 |
Why?
|
| Sphingomyelins | 1 | 1986 | 105 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 585 | 0.070 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 1506 | 0.070 |
Why?
|
| Genetic Techniques | 1 | 2009 | 428 | 0.060 |
Why?
|
| Diphosphonates | 1 | 2011 | 634 | 0.060 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 13386 | 0.060 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 418 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2014 | 2765 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2006 | 396 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1191 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 376 | 0.060 |
Why?
|
| Pulmonary Surfactants | 1 | 1986 | 162 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2014 | 4111 | 0.060 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 242 | 0.060 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 3899 | 0.060 |
Why?
|
| Awareness | 1 | 2009 | 649 | 0.060 |
Why?
|
| Mammaplasty | 3 | 2024 | 1232 | 0.060 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 102 | 0.060 |
Why?
|
| Imidazoles | 1 | 2011 | 1172 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 2131 | 0.060 |
Why?
|
| Algorithms | 5 | 2012 | 14025 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2008 | 15308 | 0.060 |
Why?
|
| Preoperative Care | 3 | 2008 | 2241 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2012 | 2082 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5103 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5874 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8663 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2009 | 728 | 0.060 |
Why?
|
| Obesity | 3 | 2023 | 12940 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 1803 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2016 | 5521 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5295 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 1702 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2000 | 4679 | 0.060 |
Why?
|
| Europe | 1 | 2011 | 3423 | 0.060 |
Why?
|
| Periodontitis | 1 | 2008 | 568 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1625 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 1668 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 793 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5493 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 1640 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3163 | 0.050 |
Why?
|
| Incidence | 3 | 2020 | 21366 | 0.050 |
Why?
|
| Genomics | 2 | 2019 | 5829 | 0.050 |
Why?
|
| Alopecia | 1 | 2007 | 412 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1472 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2011 | 1048 | 0.050 |
Why?
|
| Remission Induction | 2 | 2008 | 2392 | 0.050 |
Why?
|
| Carcinoma, Ductal | 2 | 2019 | 97 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 990 | 0.050 |
Why?
|
| Perception | 1 | 2009 | 1198 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1986 | 540 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2006 | 2509 | 0.050 |
Why?
|
| Constipation | 1 | 2007 | 564 | 0.050 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2012 | 1186 | 0.050 |
Why?
|
| Trinitrobenzenes | 2 | 1992 | 45 | 0.050 |
Why?
|
| Age of Onset | 1 | 2009 | 3307 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
| Vinca Alkaloids | 1 | 2002 | 36 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 2570 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2011 | 2137 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2002 | 150 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 2897 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 4251 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2004 | 714 | 0.050 |
Why?
|
| Biology | 1 | 2024 | 290 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 2691 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2002 | 95 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2009 | 6586 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 11067 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 2 | 2009 | 2164 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 1993 | 4744 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2008 | 1607 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2016 | 3808 | 0.050 |
Why?
|
| Thiotepa | 1 | 2001 | 66 | 0.050 |
Why?
|
| Epothilones | 1 | 2021 | 42 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2012 | 9652 | 0.050 |
Why?
|
| Breast | 3 | 2023 | 1964 | 0.050 |
Why?
|
| Epirubicin | 1 | 2001 | 81 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 70 | 0.050 |
Why?
|
| Recurrence | 3 | 2020 | 8457 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2012 | 1935 | 0.050 |
Why?
|
| Terminal Care | 1 | 2013 | 1760 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2005 | 1084 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1991 | 317 | 0.050 |
Why?
|
| Premedication | 1 | 2021 | 246 | 0.050 |
Why?
|
| Ovalbumin | 2 | 1993 | 671 | 0.050 |
Why?
|
| Breast Implants | 1 | 2024 | 407 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 569 | 0.040 |
Why?
|
| Syndrome | 1 | 2007 | 3271 | 0.040 |
Why?
|
| Bone Density | 2 | 2011 | 3546 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2014 | 12341 | 0.040 |
Why?
|
| Cisplatin | 2 | 2009 | 1652 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 901 | 0.040 |
Why?
|
| Inpatients | 1 | 2011 | 2545 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1993 | 1762 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 628 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2005 | 1594 | 0.040 |
Why?
|
| Research | 1 | 2008 | 1976 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 244 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1201 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2001 | 407 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2015 | 4642 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 1991 | 9520 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2002 | 335 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 4420 | 0.040 |
Why?
|
| Truth Disclosure | 1 | 2003 | 432 | 0.040 |
Why?
|
| Proteomics | 1 | 2012 | 3840 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 6304 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2003 | 567 | 0.040 |
Why?
|
| Animals | 12 | 2014 | 168089 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2820 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 918 | 0.040 |
Why?
|
| Osteoporosis | 2 | 2014 | 1604 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 573 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2019 | 504 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2009 | 4014 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 1995 | 1681 | 0.040 |
Why?
|
| Lung | 2 | 1986 | 9979 | 0.040 |
Why?
|
| Liposomes | 1 | 2001 | 783 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 1895 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 212 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2175 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 1993 | 10203 | 0.040 |
Why?
|
| Heart Failure | 2 | 2012 | 11701 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Proteins | 1 | 1992 | 5993 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 1393 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 4537 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2009 | 2362 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2001 | 1756 | 0.030 |
Why?
|
| Fetal Organ Maturity | 2 | 1986 | 83 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2021 | 858 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2001 | 1417 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 17897 | 0.030 |
Why?
|
| Research Design | 1 | 2012 | 6180 | 0.030 |
Why?
|
| Fluorescence Polarization | 2 | 1986 | 140 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 1993 | 1891 | 0.030 |
Why?
|
| Data Collection | 2 | 2008 | 3320 | 0.030 |
Why?
|
| ROC Curve | 1 | 2003 | 3584 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2013 | 41496 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9458 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1191 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3885 | 0.030 |
Why?
|
| Body Height | 1 | 2021 | 1566 | 0.030 |
Why?
|
| Random Allocation | 1 | 1999 | 2393 | 0.030 |
Why?
|
| Phosphatidylcholines | 2 | 1986 | 404 | 0.030 |
Why?
|
| Estrogens | 1 | 2021 | 1522 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2000 | 761 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 9025 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3571 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 1993 | 3155 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 1246 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2023 | 2049 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 934 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 489 | 0.030 |
Why?
|
| Male | 13 | 2023 | 360703 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 591 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1791 | 0.030 |
Why?
|
| Triage | 1 | 2020 | 985 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 1995 | 309 | 0.030 |
Why?
|
| Hospitalization | 1 | 2013 | 10707 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 550 | 0.030 |
Why?
|
| Federal Government | 1 | 2015 | 266 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 754 | 0.030 |
Why?
|
| Comorbidity | 1 | 2007 | 10516 | 0.030 |
Why?
|
| Alpharetrovirus | 1 | 1992 | 29 | 0.030 |
Why?
|
| Boston | 1 | 2005 | 9327 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12976 | 0.030 |
Why?
|
| Income | 1 | 2021 | 1869 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1993 | 158 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2000 | 1052 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 1381 | 0.030 |
Why?
|
| Menopause | 1 | 2000 | 1646 | 0.030 |
Why?
|
| Haptens | 1 | 1992 | 163 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1186 | 0.030 |
Why?
|
| Antigens, T-Independent | 1 | 1991 | 20 | 0.020 |
Why?
|
| Overweight | 1 | 2023 | 2418 | 0.020 |
Why?
|
| HIV-1 | 3 | 1995 | 6851 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2011 | 23419 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 123 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 36415 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 1 | 1991 | 112 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2006 | 5081 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 2058 | 0.020 |
Why?
|
| Fever | 2 | 2011 | 1618 | 0.020 |
Why?
|
| Financing, Government | 1 | 2015 | 472 | 0.020 |
Why?
|
| Amino Acid Sequence | 5 | 1995 | 13402 | 0.020 |
Why?
|
| Gene Expression | 1 | 2003 | 7571 | 0.020 |
Why?
|
| Solubility | 1 | 1992 | 1085 | 0.020 |
Why?
|
| Kinetics | 3 | 1995 | 6312 | 0.020 |
Why?
|
| Molecular Sequence Data | 5 | 1995 | 17598 | 0.020 |
Why?
|
| Health Status | 1 | 2003 | 4077 | 0.020 |
Why?
|
| Child | 1 | 2018 | 80154 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 9478 | 0.020 |
Why?
|
| Drug Information Services | 1 | 2009 | 51 | 0.020 |
Why?
|
| Cell Line | 3 | 1992 | 15545 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2015 | 624 | 0.020 |
Why?
|
| Substrate Specificity | 4 | 1995 | 1768 | 0.020 |
Why?
|
| Keratin-19 | 1 | 2009 | 33 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1892 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1991 | 1429 | 0.020 |
Why?
|
| Developing Countries | 1 | 2021 | 2863 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 2021 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2009 | 79 | 0.020 |
Why?
|
| Evidence-Based Medicine | 3 | 2009 | 3691 | 0.020 |
Why?
|
| Prevalence | 1 | 2005 | 15721 | 0.020 |
Why?
|
| Protein Precursors | 1 | 1992 | 1132 | 0.020 |
Why?
|
| Pregnancy | 3 | 2002 | 29893 | 0.020 |
Why?
|
| Alveolar Process | 1 | 2008 | 290 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7512 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 2007 | 47 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1986 | 80 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 1986 | 34 | 0.020 |
Why?
|
| Risk | 1 | 2019 | 9616 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3634 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 934 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2014 | 1185 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 883 | 0.020 |
Why?
|
| Cell Communication | 1 | 1993 | 1651 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 2261 | 0.020 |
Why?
|
| Phosphatidylethanolamines | 1 | 1986 | 129 | 0.020 |
Why?
|
| Water | 1 | 1992 | 1410 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1923 | 0.020 |
Why?
|
| Flavonoids | 1 | 2009 | 444 | 0.020 |
Why?
|
| Alveolar Bone Loss | 1 | 2008 | 387 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1986 | 573 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 1999 | 7804 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3418 | 0.020 |
Why?
|
| Antiemetics | 1 | 2006 | 186 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2008 | 711 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 1991 | 1505 | 0.010 |
Why?
|
| Paget's Disease, Mammary | 1 | 1964 | 18 | 0.010 |
Why?
|
| DNA Primers | 1 | 2009 | 2814 | 0.010 |
Why?
|
| Osteitis Deformans | 1 | 1964 | 54 | 0.010 |
Why?
|
| Paget Disease, Extramammary | 1 | 1964 | 51 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1986 | 958 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3803 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 20588 | 0.010 |
Why?
|
| Transfection | 1 | 1991 | 5748 | 0.010 |
Why?
|
| Dependovirus | 1 | 2008 | 712 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5333 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 6125 | 0.010 |
Why?
|
| Medicare | 2 | 2016 | 6774 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 161 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20118 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 14610 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 3051 | 0.010 |
Why?
|
| Review Literature as Topic | 1 | 2004 | 348 | 0.010 |
Why?
|
| Base Sequence | 2 | 2009 | 12404 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1991 | 3661 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2013 | 3024 | 0.010 |
Why?
|
| Prednisone | 1 | 2006 | 1565 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 3778 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 704 | 0.010 |
Why?
|
| Sirolimus | 1 | 2008 | 1540 | 0.010 |
Why?
|
| Pathology | 1 | 1964 | 269 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1991 | 5871 | 0.010 |
Why?
|
| Mice | 3 | 1993 | 81330 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2009 | 1129 | 0.010 |
Why?
|
| Protein Conformation | 3 | 1994 | 3933 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2008 | 1242 | 0.010 |
Why?
|
| Binding Sites | 3 | 1995 | 5988 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2003 | 431 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1991 | 4009 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22174 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12676 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15920 | 0.010 |
Why?
|
| Depression | 1 | 1999 | 8132 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 983 | 0.010 |
Why?
|
| Cardiology | 1 | 2010 | 1693 | 0.010 |
Why?
|
| Calcium | 1 | 1992 | 5719 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 1945 | 0.010 |
Why?
|
| Point Mutation | 2 | 1995 | 1593 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2011 | 18927 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 3388 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1991 | 4373 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2270 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 2024 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2001 | 15521 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 42225 | 0.010 |
Why?
|
| SEER Program | 1 | 2003 | 1453 | 0.010 |
Why?
|
| Lymphoma | 1 | 2007 | 1898 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8164 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4310 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 1812 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3453 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 4190 | 0.010 |
Why?
|
| Pain | 1 | 2011 | 5072 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8479 | 0.010 |
Why?
|
| Patient Participation | 1 | 2003 | 1445 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 7386 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1994 | 849 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 1994 | 418 | 0.010 |
Why?
|
| Catalysis | 1 | 1995 | 763 | 0.010 |
Why?
|
| Turkeys | 1 | 1992 | 44 | 0.010 |
Why?
|
| Coturnix | 1 | 1992 | 22 | 0.010 |
Why?
|
| Leukemia | 1 | 2001 | 1518 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1992 | 166 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 23705 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 88300 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 11101 | 0.010 |
Why?
|
| Models, Molecular | 2 | 1992 | 5406 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 11512 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1992 | 649 | 0.010 |
Why?
|
| Weight Gain | 1 | 2001 | 2349 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1995 | 1978 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 12052 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1991 | 346 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 5321 | 0.000 |
Why?
|
| Antigen-Presenting Cells | 1 | 1991 | 965 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1991 | 800 | 0.000 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 6919 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 4167 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1994 | 4107 | 0.000 |
Why?
|